Literature DB >> 19179338

Cyclin-dependent Kinases Phosphorylate the Cytomegalovirus RNA Export Protein pUL69 and Modulate Its Nuclear Localization and Activity.

Sabine Rechter1, Gillian M Scott, Jan Eickhoff, Katrin Zielke, Sabrina Auerochs, Regina Müller, Thomas Stamminger, William D Rawlinson, Manfred Marschall.   

Abstract

Replication of human cytomegalovirus (HCMV) is subject to regulation by cellular protein kinases. Recently, we and others reported that inhibition of cyclin-dependent protein kinases (CDKs) or the viral CDK ortholog pUL97 can induce intranuclear speckled aggregation of the viral mRNA export factor, pUL69. Here we provide the first evidence for a direct regulatory role of CDKs on pUL69 functionality. Although replication of all HCMV strains was dependent on CDK activity, we found strain-specific differences in the amount of CDK inhibitor-induced pUL69 aggregate formation. In all cases analyzed, the inhibitor-induced pUL69 aggregates were clearly localized within viral replication centers but not subnuclear splicing, pore complex, or aggresome structures. The CDK9 and cyclin T1 proteins colocalized with these pUL69 aggregates, whereas other CDKs behaved differently. Phosphorylation analyses in vivo and in vitro demonstrated pUL69 was strongly phosphorylated in HCMV-infected fibroblasts and that CDKs represent a novel class of pUL69-phosphorylating kinases. Moreover, the analysis of CDK inhibitors in a pUL69-dependent nuclear mRNA export assay provided evidence for functional impairment of pUL69 under suppression of CDK activity. Thus, our data underline the crucial importance of CDKs for HCMV replication, and indicate a direct impact of CDK9-cyclin T1 on the nuclear localization and activity of the viral regulator pUL69.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19179338      PMCID: PMC2659219          DOI: 10.1074/jbc.M805693200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44.

Authors:  Manfred Marschall; Martina Freitag; Patricia Suchy; Daniel Romaker; Regina Kupfer; Miriam Hanke; Thomas Stamminger
Journal:  Virology       Date:  2003-06-20       Impact factor: 3.616

2.  Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.

Authors:  Karen K Biron; Robert J Harvey; Stanley C Chamberlain; Steven S Good; Albert A Smith; Michelle G Davis; Christine L Talarico; Wayne H Miller; Robert Ferris; Ronna E Dornsife; Sylvia C Stanat; John C Drach; Leroy B Townsend; George W Koszalka
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

3.  MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a transcription-dependent manner.

Authors:  Annemieke A Michels; Van Trung Nguyen; Alessandro Fraldi; Valérie Labas; Mia Edwards; François Bonnet; Luigi Lania; Olivier Bensaude
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

4.  Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor.

Authors:  Annemieke A Michels; Alessandro Fraldi; Qintong Li; Todd E Adamson; François Bonnet; Van Trung Nguyen; Stanley C Sedore; Jason P Price; David H Price; Luigi Lania; Olivier Bensaude
Journal:  EMBO J       Date:  2004-06-17       Impact factor: 11.598

5.  Catalytic activity of Cdk9 is required for nuclear co-localization of the Cdk9/cyclin T1 (P-TEFb) complex.

Authors:  Giuliana Napolitano; Barbara Majello; Luigi Lania
Journal:  J Cell Physiol       Date:  2003-10       Impact factor: 6.384

Review 6.  Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication.

Authors:  Luis M Schang
Journal:  Biochim Biophys Acta       Date:  2004-03-11

Review 7.  The UL97 protein kinase of human cytomegalovirus and homologues in other herpesviruses: impact on virus and host.

Authors:  Detlef Michel; Thomas Mertens
Journal:  Biochim Biophys Acta       Date:  2004-03-11

8.  Emerging role for autophagy in the removal of aggresomes in Schwann cells.

Authors:  Jenny Fortun; William A Dunn; Shale Joy; Jie Li; Lucia Notterpek
Journal:  J Neurosci       Date:  2003-11-19       Impact factor: 6.167

9.  Mechanisms governing maintenance of Cdk1/cyclin B1 kinase activity in cells infected with human cytomegalovirus.

Authors:  Veronica Sanchez; Anita K McElroy; Deborah H Spector
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress.

Authors:  Paula M Krosky; Moon-Chang Baek; Donald M Coen
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  28 in total

1.  The cellular protein SPT6 is required for efficient replication of human cytomegalovirus.

Authors:  Daniel Cygnar; Stacy Hagemeier; Daniel Kronemann; Wade A Bresnahan
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

2.  Human cytomegalovirus UL97 kinase alters the accumulation of CDK1.

Authors:  Rachel B Gill; Scott H James; Mark N Prichard
Journal:  J Gen Virol       Date:  2012-05-02       Impact factor: 3.891

3.  Conserved herpesvirus kinases target the DNA damage response pathway and TIP60 histone acetyltransferase to promote virus replication.

Authors:  Renfeng Li; Jian Zhu; Zhi Xie; Gangling Liao; Jianyong Liu; Mei-Ru Chen; Shaohui Hu; Crystal Woodard; Jimmy Lin; Sean D Taverna; Prashant Desai; Richard F Ambinder; Gary S Hayward; Jiang Qian; Heng Zhu; S Diane Hayward
Journal:  Cell Host Microbe       Date:  2011-10-20       Impact factor: 21.023

4.  pUL69 of Human Cytomegalovirus Recruits the Cellular Protein Arginine Methyltransferase 6 via a Domain That Is Crucial for mRNA Export and Efficient Viral Replication.

Authors:  Marco Thomas; Eric Sonntag; Regina Müller; Stefanie Schmidt; Barbara Zielke; Torgils Fossen; Thomas Stamminger
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

5.  A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations.

Authors:  Corina Hutterer; Jan Eickhoff; Jens Milbradt; Klaus Korn; Isabel Zeitträger; Hanife Bahsi; Sabrina Wagner; Gunther Zischinsky; Alexander Wolf; Carsten Degenhart; Anke Unger; Matthias Baumann; Bert Klebl; Manfred Marschall
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

6.  In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses.

Authors:  Manfred Marschall; Thomas Stamminger; Andreas Urban; Steffen Wildum; Helga Ruebsamen-Schaeff; Holger Zimmermann; Peter Lischka
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

7.  Binding of the human cytomegalovirus (HCMV) tegument protein UL69 to UAP56/URH49 is not required for efficient replication of HCMV.

Authors:  Daniel Kronemann; Stacy R Hagemeier; Dan Cygnar; Stacia Phillips; Wade A Bresnahan
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

8.  Characterization of the betaherpesviral pUL69 protein family reveals binding of the cellular mRNA export factor UAP56 as a prerequisite for stimulation of nuclear mRNA export and for efficient viral replication.

Authors:  Barbara Zielke; Marco Thomas; Antje Giede-Jeppe; Regina Müller; Thomas Stamminger
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

9.  Cyclin-dependent kinase activity controls the onset of the HCMV lytic cycle.

Authors:  Martin Zydek; Christian Hagemeier; Lüder Wiebusch
Journal:  PLoS Pathog       Date:  2010-09-09       Impact factor: 6.823

10.  CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses.

Authors:  Makoto Yamamoto; Hiroshi Onogi; Isao Kii; Suguru Yoshida; Kei Iida; Hiroyuki Sakai; Minako Abe; Toshiaki Tsubota; Nobutoshi Ito; Takamitsu Hosoya; Masatoshi Hagiwara
Journal:  J Clin Invest       Date:  2014-07-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.